HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 973-984 of 4,505
Drug study icon
CompletedNCT05953740

MK-5720 in people with Schizophrenia (MK-5720-001)

What is this study about?

This study evaluated the safety of MK-5720 for people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Glendale
SchizophreniaMedication studyAges 18–60
Countries
United States
Sponsor
Merck Sharp & Dohme LLC
Drug study icon
CompletedNCT01354353

Safety study of safety and Tolerability in schizophrenia

What is this study about?

Researchers compared LY2140023 and Aripiprazole, tracking side effects to assess safety and tolerability in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Garden Grove
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Denovo Biopharma LLC
Drug study icon
CompletedNCT01116830

Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction for schizophrenia

Official study title

A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder

This study has finished and is no longer accepting participants.

In Orangeburg
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Hoffmann-La Roche
Drug study icon
CompletedNCT00236379

Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) for schizophrenia

Official study title

A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Janssen, LP
Drug study icon
CompletedNCT01617187

Asenapine for schizophrenia

What is this study about?

This study evaluated the safety and effectiveness of Asenapine for people with schizophrenia.

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18+
Countries
Sponsor
Organon and Co
Drug study icon
CompletedNCT04115319

Safety study of investigational Drug in schizophrenia

What is this study about?

Researchers compared SEP363856 and quetiapine XR, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Cerritos
SchizophreniaMedication studyAges 18–65
Countries
United States, Romania, Russia, + 1 other
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT02713282

Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia

What is this study about?

Researchers studied Paliperidone palmitate 3 month formulation (PP3M) to find out how it affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Rijeka
SchizophreniaMedication studyAges 18–50
Countries
France, United Kingdom, Croatia, + 12 others
Sponsor
Janssen-Cilag Ltd.
Other study type icon
CompletedNCT03666715

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in adults with Schizophrenia in Portugal

Official study title

A Multicenter Retrospective Study to Analyse the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Patients With Schizophrenia in Portugal

This study has finished and is no longer accepting participants.

In Porto
SchizophreniaObservational studyAges 18–55
Countries
Portugal
Sponsor
Janssen-Cilag Farmaceutica Ltda.
Drug study icon
CompletedNCT05145413

KarXT for schizophrenia

Official study title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Phoenix
SchizophreniaMedication studyAges 18–65
Countries
United States, United Kingdom, Bulgaria, + 5 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.